NCT00867607View on ClinicalTrials.gov

Safety, Tolerability, and Efficacy of 21 Days Dermal Application of MRX-6 on Mild to Moderate Contact Dermatitis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

April 30, 2013

Study Completion Date

March 31, 2014

Conditions
Allergic Contact Dermatitis
Interventions
DRUG

MRX-6

b.i.d treatment for 21 days

DRUG

Steroid

b.i.d. 21 days

Trial Locations (2)

Unknown

dermatology department, Hadassah university hospital, Jerusalem

Department of Dermatology, Hadassah Hospital, Ein Karem, Jerusalem

Sponsors
All Listed Sponsors
collaborator

Morria Biopharmaceuticals PLC

INDUSTRY

lead

Hadassah Medical Organization

OTHER